Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) ...
ABT's Nutrition rebound and FreeStyle Libre growth fuel momentum, but currency swings and macro pressures could cloud ...
Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system ...
GlobalData on MSN
Abbott reports positive FreeDM2 study results for CGM
The study was carried out at 24 clinical sites across the UK and included 303 participants.
The integration supports treatment decisions across cancer care stages and helps reduce administrative tasks for clinicians.
NEW YORK, NY, UNITED STATES, April 3, 2026 /EINPresswire.com/ -- The IoT healthcare market reached $176 billion in 2025 ...
Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.
Is ABT a good stock to buy? We came across a bullish thesis on Abbott Laboratories on Compounding Dividends’s Substack by TJ ...
Zacks Investment Research on MSN
Reasons to hold Tandem Diabetes stock in your portfolio for now
Tandem Diabetes Care, Inc.’s TNDM impressive product launches are expected to bolster growth in the upcoming quarters. A strong solvency looks encouraging. However, concerns loom over fierce ...
Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results